PARIS--(BUSINESS WIRE)--Regulatory News:
“We are pleased with the positive Phase 3 results for telotristat etiprate released early August, which are an important milestone in our strategy to become global leaders in neuroendocrine tumors.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the third quarter and first nine months of 2015.
Help employers find you! Check out all the jobs and post your resume.
“We are pleased with the positive Phase 3 results for telotristat etiprate released early August, which are an important milestone in our strategy to become global leaders in neuroendocrine tumors.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the third quarter and first nine months of 2015.
Help employers find you! Check out all the jobs and post your resume.
